Giuliana Rizzuto

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Journal: Transplantation and cellular therapy

Published: April 14, 2026

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Journal: Clinical and experimental medicine

Published: March 27, 2026

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Journal: Bone marrow transplantation

Published: March 18, 2026

CMV Reactivations During and After Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

CMV Reactivations During and After Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

Journal: Mediterranean journal of hematology and infectious diseases

Published: August 09, 2025

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

Journal: Blood cancer journal

Published: June 24, 2025

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Journal: Blood cancer journal

Published: January 08, 2025

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.

Journal: Blood advances

Published: July 19, 2024

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.

Journal: Frontiers in immunology

Published: July 03, 2024

Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.

Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.

Journal: Bone marrow transplantation

Published: February 27, 2024

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

Journal: Cancer

Published: July 19, 2022

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.

Journal: Clinical case reports

Published: July 22, 2021

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Journal: Blood cancer journal

Published: May 23, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026